IDT Corp. operates as a holding company. The firm engages in the distribution and market of communications and payment services. It operates through the following segments: Fintech, National Retail Solutions, Net2phone, Traditional Communications, and Corporate. The Fintech segment is involved in international money remittance and related value transfer services. The National Retail Solutions segment refers to an operator of a nationwide POS network providing independent retailers with store management software, electronic payment processing, and other ancillary merchant services. The Net2phone segment consists of net2phone's cloud communications and contact center offerings. The Traditional Communications segment includes IDT Digital Payments, which enables customers to transfer airtime and bundles of airtime, messaging, and data to international and domestic mobile accounts, BOSS Revolution Calling, an international long-distance calling service marketed primarily to immigrant communities in the United States and Canada, and IDT Global, a wholesale provider of international voice and SMS termination and outsourced traffic management solutions to telecoms worldwide. The company was founded by Howard S. Jonas in August 1990 and is headquartered in Newark, NJ.
相关临床试验
0
0 进行中
药物批准
24
批准总数
监管机构
1
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
- Doctors plan to request FDA approval this winter for a clinical trial testing CRISPR base editing in seven different urea cycle disorders, following the successful treatment of baby KJ with CPS1 deficiency. - The proposed "umbrella-of-umbrella" trial would allow individualized gene editing treatments to be tested in a single study, potentially leading to platform technology approval after treating five patients. - Baby KJ's personalized gene editing treatment transformed his severe CPS1 deficiency into a milder form, eliminating his need for liver transplant and representing a landmark achievement in personalized medicine. - The research team has received thousands of pleas from rare disease families since KJ's treatment success was announced in May, highlighting the urgent need for scalable gene editing infrastructure.
• Ribbon Bio has appointed Jeff Fitzgerald as Vice President, Global Head of Sales to drive commercial growth as the company launches its first product, MiroSynth™ DNA Molecules. • Fitzgerald brings over a decade of commercial leadership experience from companies including ArcherDx and IQVIA, where he demonstrated success in scaling operations and delivering revenue growth. • MiroSynth™ DNA utilizes Ribbon Bio's proprietary algorithm-driven technology and enzymatic assembly process to deliver highly complex and accurate synthetic DNA for applications in biopharma and life sciences.
